Multimodal treatment of gastrointestinal tract tumors: Consequences for surgery

World Journal of Surgery

Volumn 29, Issue 8, 2005, Pages 940-948

  Siewert, J Rüdiger ^a   Stein, Hubert J ^a   Von Rahden, Burkhard H A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; EARLY CANCER; GASTROINTESTINAL TUMOR; HUMAN; MEDICAL DECISION MAKING; METABOLISM; METASTASIS; MUCOSA; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PALLIATIVE THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RISK ASSESSMENT; SUBMUCOSA; SURGICAL APPROACH; TUMOR REGRESSION; ARTICLE; PATHOLOGY; RADIOGRAPHY; SURVIVAL;

COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 21844456590     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-005-0010-4     Document Type: Conference Paper

References (29)

1. Stein HJ, Siewert JR. Improved prognosis of resected esophageal cancer. World J. Surg. 2004;28:520-525
2. Stein HJ, von Rahden BHA, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch. Surg. 2004 Jul 14
3. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J. Clin. Oncol. 2004;22:3805-3812
4. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann. Surg. 2004;240:1027-1034
5. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann. Surg. 2000;232:743-752
6. Bartels H, Stein HJ, Siewert JR. Risk analysis in esophageal surgery. Recent Results Cancer Res. 2000;155:89-96
7. Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br. J. Surg. 1998;85:840-844
8. Schlag PM, Bembenek A, Schulze T. Sentinel node biopsy in gastrointestinal-tract cancer. Eur. J. Cancer 2004;40:2022-2032
9. Kitagawa Y, Kitajima M. Lymphatic mapping for upper gastrointestinal malignancies. Semin. Oncol. 2004;31:409-414
10. Kitagawa Y, Fujii H, Mukai M, et al. Current status and future prospects of sentinel node navigational surgery for gastrointestinal cancers. Ann. Surg. Oncol. 2004;11(3 Suppl):242S-244S
11. Fujii H, Kitagawa Y, Kitajima M, et al. Sentinel node of malignancies originating in the alimentary tract. Ann. Nucl. Med. 2004;18:1-12
12. Burian M, Stein HJ, Sendler A, et al. [Sentinel lymph node mapping in gastric and esophageal carcinomas]. Chirurg 2004;75:756-760
13. Burian M, Stein HJ, Sendler A, et al. Sentinel node detection in Barrett's and cardia cancer. Ann. Surg. Oncol. 2004;Mar;11(3 Suppl):255S-258S
14. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 2003;185:538-543
15. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann. Surg. Oncol. 2003;10:754-761
16. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733
17. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 1998;339:1979-1984
18. Siewert JR, Stein HJ, Feith M, et al.Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann. Surg. 2001;234:360-367
19. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc ASCO 2003;998 (abstract)
20. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 2004;351:1731-1740
21. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 2001;345:638-646
22. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 1997;336:980-987
23. Becker K, Mueller JD, Schulmatcher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530
24. Bruecher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann. Surg. 2001;233:300-309
25. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell, carcinoma: results of a prospective phase-II trial. Eur. J. Surg. Oncol. 2004;30:963-971
26. Ott K, Weber WA, Fink U, et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J. Surg. 2003;27:1035-1039
27. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 2001;19:3058-3065
28. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J. Clin. Oncol. 2003;21:4604-4610
29. Heidecke CD, Weighardt H, Feith M, et al. Neoadjuvant treatment of esophageal cancer: immunosuppression following combined radiochemotherapy. Surgery 2002;132:495-501